[1]刘世军,赵海峰,唐志书,等.薄层扫描法测定补阳还五胶囊黄芪甲苷的含量[J].西部中医药,2016,29(01):30-32.
　LIU Shijun,ZHAO Haifeng,TANG Zhishu,et al.Determination of Astragaloside Ⅳ in BuYang HuanWu Capsules by TLC[J].Western Journal of Traditional Chinese Medicine,2016,29(01):30-32.
点击复制

薄层扫描法测定补阳还五胶囊黄芪甲苷的含量()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
29
期数:
2016年01期
页码:
30-32
栏目:
出版日期:
2016-01-15

文章信息/Info

Title:
Determination of Astragaloside Ⅳ in BuYang HuanWu Capsules by TLC
文章编号:
1004-6852(2016)01-0030-03
作者:
刘世军，赵海峰，唐志书，崔春利，刘红波，梁艳妮
陕西中医药大学陕西中药资源产业化协同创新中心，陕西 咸阳 712083
Author(s):
LIU Shijun, ZHAO Haifeng, TANG Zhishu, CUI Chunli, LIU Hongbo, LIANG Yanni
Shaanxi Collaborative Innovation Center of Chinese Medicinal Resource Industrialization of Shaanxi University of Chinese Medicine, Xianyang 712083, China
关键词:
补阳还五胶囊; 黄芪甲苷; 质量标准; 薄层扫描法
Keywords:
BuYang HuanWu capsules;  astragaloside Ⅳ;  quality standard;  thin layer scanning
分类号:
R917
文献标志码:
A
摘要:
目的：建立薄层扫描法测定补阳还五胶囊黄芪甲苷含量的方法。方法：硅胶G薄层板，氯仿-甲醇-水(13∶6∶2)10℃以下放置过夜的下层溶液展开，λS=530 nm，λR=700 nm。结果：线性范围为0.980～6.860 μg，平均回收率为99.49%，精密度RSD为0.846%。结论：该方法简便，灵敏度高，重复性好，回收率高，可用于补阳还五胶囊中黄芪甲苷的含量测定。
Abstract:
Objective: To establish the determination method of astragaloside Ⅳ in BuYang HuanWu capsules by thin layer scanning (TLC). Methods: Silica gel G TLC-scanner, loroform-methanol-water (13:6:2), placed below 10℃ and stayed overnight, the lower solution was taken out and spread, λS=530 nm, λR=700 nm. Results: Linearity range was between 0.980 and 6.860 μg, average recovery rate was 99.49%, precision RSD was 0.846%. Conclusion: The method, simple, sensible, reproducible and with high recovery rate, could be used to content determination of astragaloside Ⅳ in BuYang HuanWu capsules.

相似文献/References:

[1]吴忠民,贾 忠△,李喜香,等.黄芪党参颗粒中黄芪甲苷含量的HPLC测定方法[J].西部中医药,2012,25(10):23.
　WU Zhong-min,JIA Zhong,LI Xi-xiang,et al.HPLC Determination of Astragaloside Ⅳ in HuangQi DangShen Granule[J].Western Journal of Traditional Chinese Medicine,2012,25(01):23.
[2]李红,王胜,沈明霞,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织碱性成纤维细胞生长因子(bFGF)表达的影响[J].西部中医药,2015,28(12):21.
[3]李红,沈明霞,谢海彬,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织CD34表达的影响[J].西部中医药,2015,28(09):6.
[4]李彩东,王信,张伟.参芪心舒胶囊中黄芪甲苷、芍药苷和丹参酮ⅡA含量的测定*[J].西部中医药,2013,26(10):17.
　LI Caidong,WANG Xin,ZHANG Wei.Assaying of Astragaloside Ⅳ, Peoniflorin and TanshinoneⅡA in ShenQi XinShu Capsule[J].Western Journal of Traditional Chinese Medicine,2013,26(01):17.
[5]王晓琳,张平.黄芪饮片与黄芪配方颗粒有效成分含量比较[J].西部中医药,2017,30(02):25.
　WANG Xiaolin,ZHANG Ping.Comparsion of Effective Elements Contents between Slices of Prepared HuangQi and Formula Granules of HuangQi[J].Western Journal of Traditional Chinese Medicine,2017,30(01):25.
[6]武向丽.黄芪甲苷对实验性糖尿病大鼠睾丸组织的保护作用[J].西部中医药,2017,30(11):32.
　WU Xiangli.The Protective Effects of Astragalosides IV on Testicular Tissue of Experimental Diabetic Rats[J].Western Journal of Traditional Chinese Medicine,2017,30(01):32.
[7]刘建平,何建峰.黄芪甲苷对大鼠肺缺血再灌注损伤的保护作用及其机制研究[J].西部中医药,2018,31(02):21.
　LIU Jianping,HE Jianfeng.Study on the Protective Effects of Astragaloside IV to the Rats Suffering from Lung Ischemical Reperfusion Injury and Its Mechanism[J].Western Journal of Traditional Chinese Medicine,2018,31(01):21.
[8]隋晓丽,张红艳,田晓倩,等.肺抑瘤合剂质量标准研究[J].西部中医药,2018,31(09):46.
　SUI Xiaoli,ZHANG Hongyan,TIAN Xiaoqian,et al.Study on Quality Standard of Pulmonary Tumor-inhibiting Mixture[J].Western Journal of Traditional Chinese Medicine,2018,31(01):46.
[9]杨长花,程芬,李慧,等.4个主要黄芪产地黄芪质量比较[J].西部中医药,2019,32(01):27.
　YANG Changhua,CHENG Fen,LI Hui,et al.Quality Comparisons of HuangQi Collected from Four Major Producing Areas[J].Western Journal of Traditional Chinese Medicine,2019,32(01):27.
[10]王超慧.黄芪甲苷对局灶性脑缺血再灌注后神经细胞凋亡的影响[J].西部中医药,2019,32(02):17.
　WANG Chaohui.Influence of Astragaloside IV on Nerve Cells Apoptosis after Focal Cerebral Ischemia/Reperfusion[J].Western Journal of Traditional Chinese Medicine,2019,32(01):17.
[11]刘世军,赵海峰,唐志书△,等.正交设计法优选补阳还五胶囊提取工艺[J].西部中医药,2016,29(04):32.
　LIU Shijun,,et al.Optimization of Extraction Process of BuYang HuanWu Capsules by Orthogonal Design[J].Western Journal of Traditional Chinese Medicine,2016,29(01):32.

备注/Memo

备注/Memo:
*基金项目：陕西省重点创新团队计划(编号2012KCT-20)。作者简介：刘世军(1974—)，男，博士学位，高级工程师。研究方向：天然产物研究及中药制剂与质量标准研究。
更新日期/Last Update: 2016-01-15